Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
December 07, 2022 07:45 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private...
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
December 07, 2022 07:30 ET
|
Vor Biopharma
Trem-cel (formerly VOR33) successfully manufactured and engrafted normallyBlood counts successfully maintained following post-transplant treatment with MylotargConference call scheduled for today,...
Vor Bio to Participate in Upcoming Investor Conferences
November 22, 2022 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
November 10, 2022 16:15 ET
|
Vor Biopharma
Initial clinical data for VOR33 on track for Q4 2022Eyal C. Attar, M.D. appointed as Chief Medical OfficerInitiated in-house clinical manufacturing at Cambridge, MA headquarters CAMBRIDGE, Mass.,...
Vor Bio to Participate in Upcoming Investor Conferences
November 01, 2022 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
October 12, 2022 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief...
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
October 11, 2022 08:00 ET
|
Vor Biopharma
-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term engraftment and persistence of editing -Data presented at European...
Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters
September 28, 2022 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the opening of its new in-house clinical...
Vor Bio to Participate in Upcoming Investor Conferences
September 06, 2022 16:15 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update
August 11, 2022 16:15 ET
|
Vor Biopharma
Initial clinical data for patients treated with Vor Bio’s engineered HSC candidate VOR33 on track for Q4 2022In-house manufacturing facility in Cambridge, MA operational in Q4 2022Data presented at...